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Vaccination is an excellent method for prevention of life-threatening diseases. Children infected 
with human immunodeficiency virus (HIV) have an increased susceptibility to, and develop more 
severe complications from, all infections1, even in the era of combination antiretroviral therapy 
(cART). Streptococcus pneumoniae is the most common cause of bacterial pneumonia and is 
responsible for significant morbidity and mortality in children and adults infected with HIV2. The 
significant burden of varicella-associated disease in children with HIV infection is also widely 
recognised3. 
 
HIV-infected children often have impaired immune responses to vaccines compared with their 
HIV-uninfected counterparts4. However, studies in children with stable HIV disease have 
demonstrated safety and generally protective responses to the pneumococcal conjugate5,6  and 
varicella7 vaccines. Administration of these vaccines is therefore now advised for HIV-infected 
children in addition to the routine immunizations given to all children and a recommended 
schedule has recently been published4. However, in the UK and many countries worldwide, HIV-
infected children often do not receive all recommended vaccines and therefore remain 
vulnerable to disease8,9. Data on rates of routine vaccination of HIV-infected children in the UK 
are not available in the CHIPS database; however, a 2009 audit of vaccine coverage among 
HIV-infected children attending 3 London clinics revealed that rates of immunization were 
extremely low, with only 28% receiving the pneumococcal conjugate vaccine (PCV7, introduced 
in 2006) and none receiving a varicella vaccine10. 
 
This study aimed to define the burden of infections due to invasive pneumococcal disease (IPD) 
and varicella zoster infections (VZ) in HIV-infected children in the UK and Ireland over the last 16 
years. These data will, in turn, provide a baseline measure for assessing the impact of recent 
guidelines on the use of these vaccines in this population4. 
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MATERIALS AND METHODS 
 
The Collaborative HIV Paediatric Study (CHIPS) has been described in detail elsewhere11,12.  
Briefly, it is a multicentre observational cohort study of virtually all HIV-infected children receiving 
pediatric care in the UK and Ireland. All hospitalizations, defined as any admission for in-patient 
care for any duration or cause among children aged <18 years, and deaths, were reviewed. The 
primary cause of hospitalization was categorised according to the ICD-10 coding system 
(Appendix 1).  Admissions with the stated primary cause of IPD, VZ, or all-cause lower 
respiratory infections between 1 January 1996 and 31 December 2011 were extracted from the 
CHIPS database. 
 
Microbiological confirmation of cases of IPD, and serotype where available, were obtained 
through direct contact with the reporting clinicians. Similarly, cause of death and whether the 
death occurred in hospital were verified with the clinician. Characteristics of children with VZ and 
IPD admissions were described, and incidence rates of first admissions per 1000 patient years 
(PYs) were calculated by ART status at the time of the admission.  In the case of multiple 
admissions, only characteristics at the time of the first admission were used. ART status was 
categorized as: on combination ART for at least 6 months prior to the admission (cART defined 
as any combination regimen of 3 or more antiretroviral drugs); or not on cART (i.e. no ART, 
mono or dual therapy, or cART for less than 6 months).  At least 6 months of cART was chosen 
as an adequate duration of ART to ensure viral suppression and CD4 reconstitution13 before the 
opportunistic infection was acquired. If a child had started cART it was assumed that s/he 
remained on cART during follow-up without interruption.  Chi square tests were used to compare 
categorical variables, t tests to compare means, and Wilcoxon rank-sum and non-parametric 
equality of medians tests to compare medians from two and three groups respectively.  All 
analyses were conducted using STATA 12 (College Station, Texas). 
 
Rates of admissions for pneumococcal, varicella and zoster disease for all children (HIV-
uninfected as well as HIV-infected) aged 0-14 years in England were acquired from Hospital 
Episode Statistics (HESonline14) and the Office for National Statistics15 for the period January 
1999 to December 2011, using relevant ICD-10 codes (Appendix 1). These were used as the 
best available group for comparison with the CHIPS cohort16,17. 
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RESULTS 
 
A total of 1,785 children were followed in the CHIPS cohort between 1 January 1996 and 31 
December 2011 and 3,905 hospital admissions among 1,119 children were recorded over this 
period. Of these, 23 admissions in 22 children were due to IPD, 107 admissions in 99 children 
were due to varicella and 89 admissions in 79 children were due to herpes zoster; a combined 
total of 196 admissions in 172 children for varicella zoster (VZ). Three children had both IPD and 
VZ admissions; for two, the VZ admission preceded the IPD admission by at least 7 months, and 
one child had both infections concurrently. A total of 156 admission days were attributable to IPD 
and 873 days for VZ. Combined admissions for both diseases accounted for around 5% of all 
admissions each year (Figure 1).  IPD admissions were generally low over the whole time 
period, while admissions with VZ appear to have declined in absolute numbers (similar to trends 
in the overall number of hospital admissions in the time period11), but not as a proportion of all 
admissions. 
 
Table 1 presents characteristics of children admitted with IPD or VZ compared to those without 
IPD or VZ admissions. There was no difference in sex, route of HIV transmission, place of birth, 
median age at HIV diagnosis or CD4 count / % at HIV diagnosis between the three groups. 
There was only one admission of VZ that was the child’s presenting illness at HIV diagnosis, all 
other admissions of IPD and VZ were in children with established HIV-infection. A higher 
proportion of children admitted with IPD or VZ were diagnosed with HIV at a later clinical stage 
(CDC stage B or C) compared to those with no admissions (36.8%, 29.7% and 22.1% 
respectively, p=0.030).  Children with episodes of IPD and VZ were more likely to have started 
cART during follow-up compared to children with no admissions (94.7%, 91.3% and 80.2%, 
p=0.004). For those starting cART, median age and CD4% at the start of cART were similar 
across the three groups (p=0.164). 
 
Table 2 shows characteristics of children at first admission for IPD or VZ by cART status at 
admission. For IPD, 3 (15.8%) children had taken cART for at least 6 months prior to the 
admission, and 16 (84.2%) had not.  For VZ, 59 (34.3%) had taken cART for at least 6 months 
and 113 (65.7%) had not.  For both IPD and VZ, median age at first admission was higher in 
children on cART compared to those not taking cART (IPD 14.5 v 5.7 years, p=0.025; VZ 10.5 v 
6.0 years, p<0.001). Although not significant, IPD admissions were more common in later 
calendar years for all children in CHIPS regardless of cART status (p=0.705).  For VZ, a higher 
proportion of admissions for children not on cART were in earlier years, whilst admissions in 
those on cART were more common in later calendar years (p<0.001).  There was no difference 
in duration of admission by cART status for IPD or VZ.  For IPD and VZ admissions, there was 
no significant difference between median CD4% or count at admission among those on cART 
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compared to those not on cART; however for VZ, median viral load was significantly lower in the 
cART group (3.9 v 4.5, p=0.029).  
 
In 4 of the 22 children with IPD the pneumococcal serotype (ST) was confirmed: one case of 9V, 
one of 19F, and 2 cases of 23F.  
 
There were no deaths associated with hospitalization due to IPD but 2 cases where 
disseminated varicella was associated with death, one of which was the child’s first presentation 
of HIV. There were 2 other deaths that were recorded by CHIPS but occurred without hospital 
admission: a 2-year old child died from pneumococcal disease with previous exposure to cART 
but was not on ART at death (1996); and a 6-year old died during an episode of chicken pox and 
was subsequently diagnosed with HIV (2004). 
 
Incidence rates per 1000 person years (PYs) for all admissions of IPD, varicella and zoster are 
presented in Table 3, along with rates for all children in England aged 0-14 years in a similar 
time period.  Incidence rates and rate ratios for all three infections were much higher for HIV-
infected children not on cART than those on cART, and rates were also higher for those on 
cART compared to all children in England.  For example, for zoster, the incidence rate for HIV-
infected children not on cART was 12.2 per 1000 PYs (95% CI 9.0-16.3), compared to 3.5 (95% 
CI 2.4-5.0) for those on cART, and 0.03 (95% CI 0.03-0.04) for all children in England.  In 
addition, the hospitalization incidence rate for all-cause lower respiratory infections in HIV-
infected children was 46.1 cases per 1000 PYs (95% CI 39.7-53.2) for those not on cART and 
6.4 (95% CI 4.8-8.2) for those on cART. This is 1.7-fold higher than for all children aged 0-14 
years in England (3.8/1000 PYs) and 12-fold higher than the incidence in HIV-infected children 
not on cART. 
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DISCUSSION 
 
In this study we found a much higher incidence rate of IPD and VZ hospitalization in HIV-
infected children in the UK and Ireland over the last 15 years compared to the general 
population of children, suggesting a considerable burden of morbidity from potentially vaccine-
preventable infections in this group. The majority of this burden appears to be related to VZ 
disease although it is apparent that the rate of admission has declined over the last 15 years. 
This may partly reflect changing demographics as many now enter the cohort as older children 
because they are born overseas11, and because there are fewer infected infants born in the UK 
and Ireland due to effective prevention of mother-to-child transmission. Although admissions for 
VZ in children not on cART have steadily declined, likely due to the trend towards earlier 
commencement of cART, admissions for VZ in children on cART remains static, a rate that may 
not necessarily reflect clinical need as it may be confounded by the clinician’s increased 
propensity for admitting a HIV-infected child. The small but apparent increase in pneumococcal 
admissions may reflect less complete reporting in the earlier years of the cohort since data from 
1996-2000 was acquired from retrospective reporting12.  
 
Overall there was no discernible trend in age or CD4% at HIV diagnosis between children with 
IPD/VZ disease and those with no IPD/VZ admissions, and similarly no difference in age or 
CD4% at the start of cART. Although numbers are small, CDC stage at HIV diagnosis was more 
advanced in children who were subsequently admitted with IPD and VZ, raising the question of 
whether these children were more immunocompromised than the rest of the cohort. Although 
there was no significant difference in CD4% at the time of commencing cART for the three 
groups, this measure may not adequately reflect CD4 subpopulations, such as memory and 
naïve cells, which may differ between individuals with similar CD4 cell counts and have different 
functional properties18.  
 
The majority of children who did have IPD or VZ admissions were not on cART at the time of 
their admission, and the increased rates of admission for all three infections in children not 
taking cART is clear, a finding which is also reported in adult studies19. Given that there was a 
higher proportion with CDC stage B/C disease at diagnosis in the children with IPD/VZ 
admissions, it is conceivable that earlier introduction of cART might have prevented these 
infections. There was no evidence for a difference in duration of IPD and VZ admissions by 
cART status, although numbers were small. 
 
The varicella vaccine has been available in the UK since 2002 for use in seronegative 
healthcare workers and families who live with an immunocompromised individual but not 
recommended for children with HIV20. Studies from the USA have demonstrated VZ vaccine 
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safety in children with CD4% >15%, and effectiveness of 82% against varicella, and 100% 
against herpes zoster over median 4.4 years follow up7. Although recent evidence suggests VZ 
vaccination cannot completely prevent episodes of herpes zoster, it has been shown to be less 
likely to occur after vaccination than after natural infection21. The recently updated Paediatric 
European Network for Treatment of AIDS and Children’s HIV Association (PENTA/CHIVA) 
guidelines published in 20124 now reflect this evidence and recommend the VZ vaccine be 
routinely used in HIV-infected children in Europe. The burden of VZ in this population in the UK 
is clear from our analysis and emphasises the importance of this recommendation.  
 
Three deaths attributed to pneumonia occurred in CHIPS, and although no organism was 
identified pneumococcus is the commonest cause of bacterial pneumonia. The true burden of 
pneumococcal disease is likely to be under-estimated in both HIV-infected and uninfected 
children since the aetiology of hospitalized pneumonia cases is often undetermined. 
Streptococcus pneumoniae has been identified as the causative organism in 31% of adult 
community-acquired pneumonias (CAP) in the UK22 and in up to 89% of children with CAP23. 
Therefore, the incidence of all-cause lower respiratory infections requiring hospital admission in 
children taking cART in the CHIPS cohort (6.4/1000 PYs) might be more representative of the 
total burden of IPD in this population.  
 
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine UK 
schedule in 200618 and was superseded by the 13-valent vaccine (PCV13) in 2010. The 
conjugate vaccines have generally replaced the 23-valent polysaccharide pneumococcal 
vaccine (PPV23) which was previously recommended in children over 2 years in special risk 
groups, such as children with HIV24. There is good evidence to support the immunogenicity of 
the conjugate vaccines in both children with and without HIV-infection6,25,26. However, we know 
from audit data that the use of PCVs in this group may be sub-optimal. Since the introduction of 
PCV7 in the UK there has been a significant reduction in the incidence of IPD in all children27; 
although we haven’t shown a reduction in the CHIPS cohort. The reasons for this are unclear; 
unfortunately it is not known whether these children have been vaccinated, how long after 
vaccinations IPD occurred, or which serotypes were responsible for the majority of these 
infections (only 4 of 22 ST were identified and all are PCV7 serotypes). It is expected that 
children with HIV would benefit both through direct protection as well as through herd immunity 
although it is possible that serotype replacement, which has been well documented in the UK 
population, might have a greater adverse impact on certain populations than on others28. It is 
important that in the future data on vaccination status and responsible STs are collected for all 
children in at-risk groups who develop IPD to enable fine-tuning of vaccine recommendations if 
required.      
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One example of this is recommendations around the timing of booster doses. Despite optimal 
primary vaccination there is a well-recognized yet variable decline in protective antibody 
concentrations over time in HIV-infected children.  Rates as low as 5% protection at a median of 
six years have been reported for measles29, 43% at one year for Hib30, 38% at eight months for 
tetanus31, and 48% at five years for the pneumococcal vaccine32. Further studies are needed to 
improve our understanding of antibody decline to guide recommendations for re-vaccination and 
boosters. While vaccine-induced antibody responses are probably dependent on CD4 T-cell 
function, recent data suggest that HIV RNA viral load at vaccination can also correlate with 
vaccine failure26,33. In light of on-going studies into vaccine safety, immunogenicity and 
effectiveness it is vital that vaccination guidelines are both well-defined yet dynamic in response 
to robust, high-quality research. 
 
The CHIPS cohort is an invaluable resource for cross-sectional and longitudinal data to optimize 
the management of HIV-infected children living in the UK and Ireland. However, this study is 
likely to provide an underestimate of the burden of infections due to these vaccine preventable 
infections; for example, CHIPS does not capture the burden of illness being managed in the 
community, reflected in the 3 deaths in the database that occurred out of hospital. In addition, 
this paper does not describe children who died very soon after HIV-presentation, therefore 
before they entered the CHIPS cohort. Anecdotally there were two cases in recent years of 
children who presented with advanced HIV and died in hospital from confirmed pneumococcal 
meningitis before they entered CHIPS. Finally, the database does not capture data on vaccine 
uptake nor adherence, and we recognise these limitations. 
 
This descriptive study highlights the increased risk of admission with IPD or VZ disease in HIV-
infected children compared to their uninfected peers, a risk which is increased in children who 
have not commenced cART. Earlier initiation of cART combined with vaccination is probably 
required to optimize protection against these infections. This study provides evidence to support 
attempts to improve routine vaccination uptake as well as promoting the recent PENTA/CHIVA 
guidelines4 recommending varicella vaccination for children with stable HIV. It is the most 
complete study of this nature to date and also serves as baseline data for future surveillance 
studies of IPD and VZ disease in this vulnerable group. 
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Figure 1: Admissions of invasive pneumococcal disease (IPD) and varicella zoster 
disease (VZ): number and percentage of all admissions by year, 1996 – 2011. 
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Table 1: Characteristics of HIV-infected children in the UK/Ireland according to cause of 
hospital admission. 
 No IPD or VZ 
admissions 
(n=1600) 
 
IPD admissions 
(n=19) 
VZ admissions 
(n=172) 
p-value 
 n (%) or median [IQR]  
Female sex 821 (51.3) 11 (57.9) 96 (55.8) 0.462 
Vertical HIV transmission 1,506 (94.1) 18 (94.7) 165 (95.9) 0.705 
Born in UK/Ireland 709 (44.3) 7 (36.8) 90 (52.3) 0.152 
Age at HIV diagnosis (years) 3.6 [0.6-8.2] 3.4 [1.7-8.2] 3.0 [0.7-6.9] 0.802 
CD4% at HIV diagnosis 21 [12-30] 19 [15-28] 21 [14-28] 0.929 
CD4 count at HIV diagnosis 590 [281-1109] 943 [510-1076] 610 [269-1136] 0.576 
CDC stage at HIV diagnosis 
  NA/A 
  B/C 
 
1,246 (77.9) 
354 (22.1) 
 
12 (63.2) 
7 (36.8) 
 
121 (70.4) 
51 (29.7) 
 
0.030 
ART status ever 
  Naive 
  Mono/ dual therapy 
  cART 
 
278 (17.4) 
39 (2.4) 
1,283 (80.2) 
 
1 (5.3) 
0 (0) 
18 (94.7) 
 
10 (5.8) 
5 (2.9) 
157 (91.3) 
 
0.004 
Age at start of cART (years) 
for those on cART 
6.6 [2.3-10.7] 7.7 [5.1-10.9] 6.6 [3.8-10.7] 0.637 
CD4% at start of cART for 
those on cART 
15 [9-22] 17 [14-24] 15 [9-22] 0.164 
CD4 count at start of cART 330 [164-659] 449 [287-756] 312 [173-646] 0.569 
IPD = Invasive pneumococcal disease, VZ = varicella zoster disease, cART = combination of 3 
antiretroviral drugs for at least 6 months, IQR = interquartile range. 
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Table 2: Characteristics of pneumococcal (IPD) and varicella (VZ) first admissions by 
cART status at admission. 
 IPD (n=19) VZ (n=172) 
 Not on cART 
(n=16) 
On cART 
(n=3) 
p-value Not on cART 
(n=113) 
On cART 
(n=59) 
p-value 
 n (%) or median [IQR]  n (%) or median [IQR]  
Age at first 
admission (years) 
5.7  
[3.5-10.8] 
14.5  
[11.7-16.0] 
0.025 6.0  
[3.6-10.0] 
10.5  
[6.6-13.5] 
<0.001 
Year of first 
admission 
  1996-2000 
  2001-2005 
  2006-2011 
 
 
3 (18.8) 
5 (31.3) 
8 (50.0) 
 
 
0 (0.0) 
1 (33.3) 
2 (66.7) 
 
 
0.705 
 
 
56 (49.6) 
39 (34.5) 
18 (15.9) 
 
 
13 (22.0) 
26 (44.1) 
20 (33.9) 
 
 
0.001 
First admission 
duration (days) 
5.0  
[3.5-6.0] 
3.0  
[3.0-8.0] 
0.572 5.0  
[2.0-7.0] 
4.0  
[2.0-6.0] 
0.657 
CD4% at first 
admission 
17.0  
[13.5-23.0] 
36.0  
[19.0-39.0] 
0.060 19.0  
[12.0-25.0] 
22.0  
[12.0-29.0] 
0.122 
CD4 count at first 
admission 
572 
[425-805] 
629 
[287-1213] 
0.773 425 
[280-782] 
521 
[238-987] 
0.509 
Log10 viral load at 
first admission 
4.5  
[4.3-5.4] 
2.1  
[1.7-5.1] 
0.166 4.5  
[3.6-5.0] 
3.9  
[2.6-4.8] 
0.029 
IPD = Invasive pneumococcal disease, VZ = varicella zoster disease, cART = combination of 3 
antiretroviral drugs for at least 6 months, IQR = interquartile range. 
 
 
Table 3: Incidence rates (95% confidence intervals) per 1000 person years and relative 
risk of all admissions for pneumococcal (IPD) and varicella disease for HIV-infected 
children on and off cART compared to all children. 
 IPD Varicella Zoster 
Admission rate of HIV-infected children aged 0-
17 years not on cART in UK/Ireland, 1996-2011 
4.7 (2.8-7.4) 19.8 (15.6-24.7) 14.1 (10.6-18.3) 
Admission rate of HIV-infected children aged 0-
17 years on cART in UK/Ireland, 1996-2011 
0.5 (0.2-1.3) 3.4 (2.3-4.8) 3.8 (2.7-5.3) 
Admission rate for all children aged 0-14 years 
in England, 1999-2011 
0.03 
(0.025 - 0.039) 
[n=3,705] 
0.23 
(0.18 - 0.27) 
[n=26,421] 
0.03 
(0.025 – 0.031) 
[n=3,287] 
Rate ratio of the three admission rates above*:  
(HIV-infected not on cART/on cART/all children) 
156.7/ 16.7/ 1 86.1/ 14.8/ 1 470/ 126.7/ 1 
* Admission rate ratio for all hospital admissions of IPD, varicella and herpes zoster among HIV-infected 
children taking or not taking cART, compared with admissions among HIV-uninfected children. IPD = 
Invasive pneumococcal disease, cART = combination of 3 antiretroviral drugs for at least 6 months. 
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Supplementary digital content legend: 
 
Appendix 1: ICD-10 codes used to acquire admission data for HIV-uninfected children 
aged 0 to 14 years in England12. 
Pneumococcal disease Varicella disease Herpes Zoster disease 
G00.1 Pneumococcal meningitis 
J13.X Pneumonia due to 
Streptococcus pneumoniae 
A40.3 Septicaemia due to 
Streptococcus pneumoniae 
B01.0 Varicella meningitis 
B01.1 Varicella encephalitis 
B01.2 Varicella pneumonia 
B01.8 Varicella with other 
complications 
B01.9 Varicella without 
complication 
B02.0 Zoster encephalitis 
B02.1 Zoster meningitis 
B02.2 Zoster with other nervous 
system involvement 
B02.3 Zoster ocular disease 
B02.7 Disseminated zoster 
B02.8 Zoster with other 
complications 
B02.9 Zoster without 
complication 
 
 
 
